Regulators in the United Kingdom have rescheduled the cannabidiol drug Epidyolex as a Schedule 5 drug, moving the medicine approved to treat severe forms of epilepsy from the much more restrictive Schedule 2 classification. GW Pharmaceuticals, the manufacturer of the medication, announced on Tuesday that the move by the Home Office would take effect in all four constituent nations of the U.K. immediately, with Northern Ireland enacting separate legislation.

Dr. Lester Grinspoon, one of the most vocal champions of marijuana legalization in the United States who promoted his advocacy in both best-selling books and Congressional testimony, died on Thursday. He was 92. A native of Massachusetts, Grinspoon studied at Harvard Medical School, and later joined the faculty there as a professor. His interest in cannabis began in the 1960s, when he said its use in the U.S. “increased explosively.”

The Swiss government wants to empower doctors to prescribe cannabis for medical purposes without authorisation. On Wednesday, the Federal Council submitted a revised version of the narcotics law to parliament for deliberation. Cannabis, whether for recreational or medical purposes, has been banned in Switzerland since 1951. However, doctors may prescribe a medicine based on this substance if they get an exceptional green light from the Federal Office of Public Health.

The rise in cannabis and its various correlated products are bringing about attitudinal perceptions and changes. The new mindset is in how we think about traditional antibiotics, and how we create responsive treatments of gut health. There is increasing anecdotal evidence of the efficacy of cannabis in treating various gastrointestinal conditions.

Australia’s Export Control Amendment (Certificate of Narcotics Exports) Bill 2020 is to improve access to global markets for the nation’s medicinal cannabis and hemp industries. In 2018, Australia’s Federal Government decided to permit the export of medical cannabis products. But according to Freshleaf Analytics, the lack of phytosanitary certification hampered progress.

Luc Springinsfeld of leading investment bank Bryan, Garnier & Co explores the European medical cannabis market and the rise of medical cannabis investment in Europe. Since the beginning of 2019, there have been a dozen mergers and acquisitions or private placement deals with values above €5m involving companies focused on medical cannabis in Europe. In total, north of €100m of new money has been invested in medical cannabis-focused companies across Europe over the past 18 months. While this represents a sharp increase compared with the period before 2019, we are still far from the levels experienced in North America, where more than $3bn was invested in the medical cannabis market through more than 450 deals in 2019.

Martha Stewart, the 78-year-old entrepreneur who built a wildly successful media empire and lifestyle brand, turned her attention last year to cannabis. Stewart is now working with Canadian company Canopy Growth to develop a line of CBD products for pets.

Fresh research is out that suggests oil extract derived from hemp may bolster your levels of the so-called “good cholesterol.”